Hepatitis B Virus Nucleic Acid Detection Kit (PCR-Fluorescence Probe Method): Technical Principles and Clinical Application Analysis

Technical Principles and Detection Advantages

The Hepatitis B Virus Nucleic Acid Detection Kit (PCR-Fluorescence Probe Method) is based on a real-time fluorescence quantitative PCR platform, utilizing specific primers and TaqMan probes targeting conserved regions of the HBV genome. During amplification, the probe is hydrolyzed by the 5′→3′ exonuclease activity of Taq polymerase, releasing a fluorescent signal, and absolute quantification of viral load is achieved by comparison with an internal standard or standard curve. This method offers high sensitivity (with a common lower limit of detection reaching 10 IU/mL) and strong specificity, effectively distinguishing different HBV genotypes and avoiding cross-reactivity interference.

Sample Collection and Processing Specifications

Clinical specimens are typically serum or plasma (EDTA anticoagulant is recommended). After collection, samples should be stored short-term at 4°C and processed as soon as possible. Nucleic acid extraction is a critical step affecting detection stability. Currently, magnetic bead methods or column extraction methods are commonly used, and accompanying kits typically provide an extraction system containing an internal control to monitor extraction efficiency and PCR inhibitors. Operators should strictly follow the instructions for sample loading, extraction, and amplification to avoid aerosol contamination.

Clinical Application Scenarios

Antiviral treatment monitoring: Changes in viral load before and after treatment are important indicators for evaluating the efficacy of nucleos(t)ide analogues or interferon, and testing every 3–6 months is generally recommended.

Occult infection screening: For patients who are HBsAg-negative but HBV DNA-positive, this kit helps identify occult hepatitis, which is of great significance especially in blood transfusion safety and organ transplantation assessment.

Evaluation of mother-to-child transmission blockade: For infants born to HBsAg-positive mothers, timely detection of HBV DNA after birth can promptly determine whether the blockade has been successful.

Quality Control and Result Interpretation

Kits should be validated against national reference materials before leaving the factory, and laboratories need to regularly participate in external quality assessment. Result reports must specify the limit of detection, quantitative range, and units (IU/mL). Samples near the cutoff value are recommended for retesting or confirmation using a more sensitive method. It should be noted that when the viral load is below the lower limit of detection, it should not be directly reported as "negative," but rather expressed as "below the lower limit of detection."